Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 701–800 of 1,002
Zhang, Y., Yao, Q., Pan, Y., Fang, X., Xu, H., Zhao, T., Zhu, G., Jiang, T., Li, S., & Cao, H. (2023) · Cancers · doi:10.3390/cancers15030682 · Cited by 18
Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer
Yuan, H., Gui, R., Wang, Z., Fang, F., & Zhao, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128774 · Cited by 18
The animal's microbiome and cancer: A translational perspective
Aluai‐Cunha, C., Pinto, C. A., Correia, A., Serra, C. R., & Santos, A. A. F. (2023) · Veterinary and Comparative Oncology · doi:10.1111/vco.12892 · Cited by 17
Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
Stoff, R., Asher, N., Laks, S., Steinberg‐Silman, Y., Schachter, J., Shapira‐Frommer, R., Grynberg, S., & Ben‐Betzalel, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1180988 · Cited by 17
Self-citationNon-pharmaceutical interventions to optimize cancer immunotherapy
Boesch, M., Baty, F., Rassouli, F., Kowatsch, T., Joerger, M., Früh, M., & Brutsche, M. H. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2255459 · Cited by 19
Minot, S. S., Garb, B. F., Roldan, A., Tang, A., Oskotsky, T., Rosenthal, C. A., Hoffman, N. G., Sirota, M., & Golob, J. L. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100639 · Cited by 18
Tsunedomi, R., Shindo, Y., Nakajima, M., Yoshimura, K., & Nagano, H. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2281482 · Cited by 15
Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC
Liu, T., Guo, Y., Liao, Y., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1333864 · Cited by 16
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
Meraz-Torres, F., Niessner, H., Plöger, S., Riel, S., Schörg, B. F., Casadei, N., Kneilling, M., Schaller, M., Flatz, L., Maček, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02941-5 · Cited by 15
Zhang, L., & Yu, L. (2024) · Medicine · doi:10.1097/md.0000000000038078 · Cited by 16
Ji, G., Zhao, J., Si, X., & Song, W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115345 · Cited by 18
Meng, Y., Sun, J. Y., & Zhang, G. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104403 · Cited by 16
Dravillas, C. E., Coleman, S. S., Hoyd, R., Caryotakis, G., Denko, L., Chan, C. H. F., Churchman, M. L., Denko, N. C., Dodd, R. D., Eljilany, I., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0170 · Cited by 21
Overcoming hurdles in cancer immunotherapy
York, A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00343-3 · Cited by 15
Caloric Restriction Alleviates Radiation Injuries In A Sex-Dependent Fashion
Li, Y., Dong, J., Xiao, H., Wang, B., Chen, Z., Zhang, S., Jin, Y., Li, Y., Fan, S., & Cui, M. (2021) · The FASEB Journal · doi:10.1096/fj.202100351rr · Cited by 16
Host Microbiomes in Tumor Precision Medicine: How far are we?
D’Amico, F., Barone, M., Tavella, T., Rampelli, S., Brigidi, P., & Turroni, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220105121754 · Cited by 17
Xin, Y., Huang, C., Zheng, M., Zhou, W., Zhang, B., Zhao, M., & Lu, Q. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103058 · Cited by 17
Baruch, E. N., Gaglani, T., & Wargo, J. A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211045853 · Cited by 17
Self-citationValles-Colomer, M., Manghi, P., Cumbo, F., Masetti, G., Armanini, F., Asnicar, F., Blanco-Miguez, A., Pinto, F., Punčochář, M., Garaventa, A., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2023.104917 · Cited by 14
“…possibility of developing microbiome-targeted complementary therapeutic approaches now used in other contexts (e.g. next-generation probiotics, 65,66 including P. dorei and Bi fi dobacterium spp, as well as faecal microbiota transplantation 40,67,68 ) to improve the symptomatology of neuroblastoma.”
BackgroundPharmacomicrobiomics in precision cancer therapy: bench to bedside
Ngoc, K. L., Pham, T. T. H., Nguyen, T. K., & Huong, P. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428420 · Cited by 20
Chandrasekaran, P., Krausz, M., Han, Y., Mitsuiki, N., Gabrysch, A., Nöltner, C., Proietti, M., Heller, T., Grou, C., Calderon, V., et al. (2025) · Microbiome · doi:10.1186/s40168-025-02028-7 · Cited by 16
Zhang, M.-J., Wen, Y., & Sun, Z. (2025) · BMC Medicine · doi:10.1186/s12916-025-04037-7 · Cited by 19
Zhou, Z., Lv, Y., Zuo, A., Zhu, X., Xu, Y., Zuo, L., Xu, H., Liu, S., Zhang, Y., Weng, S., et al. (2025) · hLife · doi:10.1016/j.hlife.2025.05.008 · Cited by 16
Ren, X., Zheng, L., Huang, L., & Zhao, J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1591745 · Cited by 17
The microbiota in radiotherapy-induced cancer immunosurveillance
Chen, J., Deutsch, É., Kroemer, G., Galluzzi, L., & Zitvogel, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01052-8 · Cited by 19
The multi-kingdom cancer microbiome
Dohlman, A. B., Pan, X., Zitvogel, L., & Iliev, I. D. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02103-7 · Cited by 18
Rauber, C., Roberti, M. P., Vehreschild, M. J. G. T., Tsakmaklis, A., Springfeld, C., Teufel, A., Ettrich, T. J., Jochheim, L. S., Kandulski, A., Missios, P., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-097802 · Cited by 18
Reprogramming prostate cancer through the microbiome
Bautista, J., Maya, W. D. C., Gancino-Guevara, K., & López-Cortés, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1690498 · Cited by 19
Role of Gut Microbiome in Oncogenesis and Oncotherapies
Peddireddi, R. S. S., Kuchana, S. K., Kode, R., Khammammettu, S., Koppanatham, A., Mattigiri, S., Gobburi, H., & Alahari, S. K. (2025) · Cancers · doi:10.3390/cancers18010099 · Cited by 15
Ramesh, A. I., Subbarayan, R., Shrestha, R., & Adtani, P. (2026) · Cancer Reports · doi:10.1002/cnr2.70455 · Cited by 32
Cancer evolution: Special focus on the immune aspect of cancer
Hu, X., Chen, Z., Wang, Z., & Xiao, Q. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.006 · Cited by 15
Zou, Y., & Yaguchi, T. (2023) · Experimental Dermatology · doi:10.1111/exd.14750 · Cited by 15
Bouferraa, Y., Fares, C., Zerdan, M. B., & Kennedy, L. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119702 · Cited by 15
A review on microbiota: relation with diseases and nutrients role
Öz, E., Şimşek, A., Şimşek, M., Tuncer, N., Bayrak, M., Çadırcı, K., Brennan, C. S., Kumar, M., Proestos, C., Brennan, M. A., et al. (2023) · International Journal of Food Science & Technology · doi:10.1111/ijfs.16530 · Cited by 15
Translational research in head and neck cancer: Molecular and immunological updates
Kumai, T., Shinomiya, H., Shibata, H., Takahashi, H., Kishikawa, T., Okada, R., Fujieda, S., & Sakashita, M. (2023) · Auris Nasus Larynx · doi:10.1016/j.anl.2023.08.006 · Cited by 15
Heterogeneity of the tumor immune microenvironment and clinical interventions
Jin, Z., Zhou, Q., Cheng, J., Jia, Q., & Zhu, B. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1015-9 · Cited by 15
Cisplatin and doxorubicin chemotherapy alters gut microbiota in a murine osteosarcoma model
Tian, Z., Qiao, X., Wang, Z., Li, X., Pan, Y., Wei, X., Lv, Z., Li, P., Du, Q., Wei, W., et al. (2024) · Aging · doi:10.18632/aging.205428 · Cited by 16
Vongsavath, T., Rahmani, R., Tun, K. M., & Manne, V. (2024) · Cancers · doi:10.3390/cancers16030499 · Cited by 16
The gut microbiome and the brain
Rykalo, N. A., Riehl, L., & Kress, M. (2024) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000717 · Cited by 16
Fecal microbiota transplantation-current perspective on human health
Cao, Z., Gao, T., Bajinka, O., Zhang, Y., & Yuan, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1523870 · Cited by 19
Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches
Pleguezuelos‐Manzano, C., Puschhof, J., & Clevers, H. C. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-095211 · Cited by 19
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
Spanu, D., Pretta, A., Lai, E., Persano, M., Donisi, C., Mariani, S., Dubois, M., Migliari, M., Saba, G., Ziranu, P., et al. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i7.1319 · Cited by 17
Liu, L., Zhang, T., Sui, Y., Li, G., Liu, L., Lu, T., Tan, H., Sun, B., Li, X., & Li, L. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106035 · Cited by 16
The potential of fecal microbiota transplantation in oncology
Lythgoe, M. P., Ghani, R., Mullish, B. H., Marchesi, J. R., & Krell, J. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.10.003 · Cited by 14
Aguilera, P., Mascardi, M. F., Belforte, F. S., Rosso, A. D., Quesada, S., Llovet, I., Iraola, G., Trinks, J., & Steinhardt, A. P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.803121 · Cited by 17
FMT for psychiatric disorders: Following the brown brick road into the future
Green, J. E., Berk, M., Loughman, A., Marx, W., Castle, D. J., McGuinness, A. J., Cryan, J. F., Nierenberg, A. A., Athan, E., Hair, C., et al. (2021) · Bipolar Disorders · doi:10.1111/bdi.13124 · Cited by 14
Unraveling the links between estrogen and gut microbiota in sex-hormone driven cancers
Tahri, A., & Amedei, A. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i9.108819 · Cited by 17
da Silva, I. P., Zimmer, L., Blay, J., Maio, M., Larkin, J., Grimm, M., Puri, S., Butler, M. O., Patel, S. P., Thakkar, P. K., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105833 · Cited by 13
From immune exclusion to exhaustion: tumor microenvironment drives therapy response
Maletin, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1785587 · Cited by 17
Training the microbiota to increase immune checkpoint blockade and to reduce toxicity
Rescigno, M. (2023) · European Journal of Immunology · doi:10.1002/eji.202250183 · Cited by 15
The Gut Microbiome and Metastatic Renal Cell Carcinoma
Meza, L., Feng, M., Lee, K., Sperandio, R., & Pal, S. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041502 · Cited by 12
The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman, D. D., Hurd, D. E., & Davar, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01431-3 · Cited by 14
Advances in the role of gut microbiota in the regulation of the tumor microenvironment (Review)
Xinyuan, T., Yu, L., Jianping, S., Rongwei, Z., Ruiwen, S., Ye, Z., Zhao, J., Chun-fang, T., Hongwei, C., & Haibin, G. (2023) · Oncology Reports · doi:10.3892/or.2023.8618 · Cited by 14
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective
Zhang, H., Wu, J., Li, N., Wu, R., & Chen, W. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188989 · Cited by 15
pH-dependent pressure-sensitive colonic capsules for the delivery of aqueous bacterial suspensions
Abdi, F., Buzhor, M. G., Zellweger, N., Zhi-Luo, & Leroux, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.048 · Cited by 13
Gut microbiota in cancer: insights on microbial metabolites and therapeutic strategies
Chen, Y., Wang, X., Ye, Y., & Ren, Q. (2023) · Medical Oncology · doi:10.1007/s12032-023-02249-6 · Cited by 14
Vu, T. T., Kim, K., Manna, M., Thomas, J. W., Remaily, B., Montgomery, E. J., Costa, T., Granchie, L., Xie, Z., Guo, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107048 · Cited by 14
The Microbiome Matters: Its Impact on Cancer Development and Therapeutic Responses
Chung, I.-Y., Kim, J. H., & Koh, A. (2024) · The Journal of Microbiology · doi:10.1007/s12275-024-00110-7 · Cited by 15
Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review
David, A., & Ari, S. L. (2024) · Integrative Cancer Therapies · doi:10.1177/15347354241269870 · Cited by 16
From pathogenesis to treatment: the impact of bacteria on cancer
Lu, J., & Tong, Q. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1462749 · Cited by 14
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
Okazawa‐Sakai, M., Sakai, S. A., Hyodo, I., Horasawa, S., Sawada, K., Fujisawa, T., Yamamoto, Y., Boku, S., Hayasaki, Y., Isobe, M., et al. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2025.36.e38 · Cited by 14
Yi, D., Li, T., Xiao, Y., Zhang, X., Hao, Q., Zhang, F., Qiu, T., Yang, G., Sun, X., Dong, Y., et al. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10728 · Cited by 16
Reens, A. L., Cabral, D. J., Liang, X., Norton, J. E., Therien, A. G., Hazuda, D. J., & Swaminathan, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643255 · Cited by 16
Toward the development of defined microbial therapeutics
Li, Y., & Honda, K. (2021) · International Immunology · doi:10.1093/intimm/dxab038 · Cited by 14
Mjaess, G., Karam, A., Aoun, F. Y., Albisinni, S., & Roumeguère, T. (2021) · Cancer · doi:10.1002/cncr.33893 · Cited by 14
Wardill, H. R., Chan, R. J., Chan, A., Keefe, D. M. K., Costello, S. P., & Hart, N. H. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06948-0 · Cited by 16
Ni, Z., Wang, S., Li, Y., Zhou, L., Zhai, D., Xia, D., & Yu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932197 · Cited by 13
The Microbiome and Liver Cancer
Myojin, Y., & Greten, T. F. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000646 · Cited by 13
Standards for fecal microbiota transplant: Tools and therapeutic advances
Belotserkovsky, I., Stabryla, L. M., Hunter, M. E., Allegretti, J. R., Callahan, B. J., Carlson, P. E., Daschner, P. J., Goudarzi, M., Guyard, C., Jackson, S. A., et al. (2024) · Biologicals · doi:10.1016/j.biologicals.2024.101758 · Cited by 14
Self-citationWang, X., Geng, Q., Jiang, H., Yue, J., Qi, C., & Qin, L. (2025) · BMC Immunology · doi:10.1186/s12865-025-00710-x · Cited by 14
The Interplay Between the Gut Microbiota and Colorectal Cancer: A Review of the Literature
Cintoni, M., Palombaro, M., Zoli, E., D’Agostino, G., Pulcini, G., Leonardi, E., Raoul, P. C., Rinninella, E., Maio, F. D., Capristo, E., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13061410 · Cited by 14
Yan, C., Chen, Y., Tian, Y., Hu, S., Wang, H., Zhang, X., Chu, Q., Huang, S., & Sun, W. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01103-3 · Cited by 14
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 18
Host and microbiome lipid metabolism in colorectal cancer development and therapy
Evora, G. M., Brauer, M., & Letellier, E. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.005 · Cited by 18
Stone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 15
Darzi, A., Shokouhfar, M., Farajee, N., Ghafari, A., Deldar, F., Eini, P., Vanan, A. G., & Bahrami, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118875 · Cited by 15
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
Silva, C. A. C., Machaalani, M., Saliby, R. M., Zhong, C., Xie, W., Pasolli, E., Piccinno, G., Dalban, C., Fidelle, M., Meurisse, A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04067-x · Cited by 17
Keivany, M. R., Asrami, E. S., Besharatloo, M., Latifi, H., & Barjasteh, A. H. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04177-7 · Cited by 16
Strain-level genetic heterogeneity and colonization dynamics drive microbiome therapeutic efficacy
Chen, K., Liu, Y., Rong, J., Dai, N., Xu, C., Li, H., Zhong, L., Wang, B., Ji, Z., Xie, S., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.02.002 · Cited by 12
Gut microbes as biomarkers of ICI response — sharpening the focus
Bhutiani, N., & Wargo, J. A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00634-0 · Cited by 12
Self-citationCrohn’s disease and breast cancer: a literature review of the mechanisms and treatment
Zhou, S., & Yu, J. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03281-0 · Cited by 12
From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer
Seo, Y. D., & Wargo, J. A. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101039 · Cited by 13
Self-citationCheng, X., Li, X., Yang, X., Fang, S., Wang, Z., Liu, T., Zheng, M., Zhai, M., Yang, Z., & Shen, T. (2023) · Cureus · doi:10.7759/cureus.42347 · Cited by 22
Poletto, S., Paruzzo, L., Nepote, A., Caravelli, D., Sangiolo, D., & Carnevale‐Schianca, F. (2023) · Cancers · doi:10.3390/cancers16010101 · Cited by 15
Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours
Fuller-Shavel, N., & Krell, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-023-01492-4 · Cited by 15
Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy
Han, Y., Zhang, Z., Zhao, K., Zhang, Y., Yin, X., Zhu, G., Wang, Z., Yan, X., Li, X., He, T., et al. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110774 · Cited by 14
Tong, L., Wan, Y., Shi, X., Liu, X., Liu, Z., Li, Y., Zhang, Y., Luo, D., & Zhu, J. (2024) · Cancer Control · doi:10.1177/10732748241253959 · Cited by 14
Chambers, L., Grencewicz, D. J., & Spakowicz, D. J. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.015 · Cited by 13
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
Vogrig, A., Dentoni, M., Florean, I., Cellante, G., Domenis, R., Iacono, D., Pelizzari, G., Rossi, S., Damato, V., Fabris, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548897 · Cited by 23
Impacts of non-nutritive sweeteners on the human microbiome
Crakes, K. R., Questell, L., Soni, S., & Suez, J. (2025) · Immunometabolism · doi:10.1097/in9.0000000000000060 · Cited by 17
Gut microbiota: Role and Association with Tumorigenesis in Different Malignancies
Ali, A., Ara, A., & Kashyap, M. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07357-6 · Cited by 12
Guenther, M., Gil, L., Surendran, S. A., Palm, M. A., Heinemann, V., von Bergwelt‐Baildon, M., Mayerle, J. V., Engel, J., Werner, J., Boeck, S. H., et al. (2022) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkac039 · Cited by 13
Rakotonirina, A., Galpérine, T., & Allémann, É. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2095901 · Cited by 16
Eickhardt‐Dalbøge, C. S., Ingham, A. C., Andersen, L. O., Nielsen, H. V., Fuursted, K., Stensvold, C. R., Larsen, M. K., Kjær, L., Christensen, S. F., Knudsen, T. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008555 · Cited by 14
Wu, D., Zhang, C., Liu, Y., Yao, J., Yang, X., Wu, S., Du, J., & Yang, X. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.02.005 · Cited by 16
Drommi, F., Calabrò, A., Vento, G., Pezzino, G., Cavaliere, R., Omero, F., Muscolino, P., Granata, B., D’Anna, F., Silvestris, N., et al. (2023) · Cancers · doi:10.3390/cancers15112893 · Cited by 14
Hes, C., & Jagoe, R. T. (2023) · BJC Reports · doi:10.1038/s44276-023-00008-8 · Cited by 16
Microbiota-based biomarkers and therapeutics for cancer management
Wu, W. K. K., & Yu, J. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00879-9 · Cited by 13
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.